Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > Ventripoint to debut new AI heart-scanning tech in Europe🚀
View:
Post by jopatclo on Oct 24, 2024 1:46pm

Ventripoint to debut new AI heart-scanning tech in Europe🚀

Ventripoint to debut new AI heart-scanning tech in Europe

 Trevor Abes Trevor Abes , The Market Online
0 Comments| 2 hours ago
 

 2

  • Ventripoint Diagnostics (TSXV:VPT), an artificial intelligence healthcare stock focused on heart analysis technology, has received the European Union’s CE certification for its latest offering, VMS+ 4.0
  • The solution offers affordable results equivalent to magnetic resonance imaging
  • Ventripoint is an industry leader in applying AI technology to echocardiography
  • Ventripoint Diagnostics stock has given back 11.11 per cent year-over-year, but has gained 33.33 per cent since 2019

Ventripoint Diagnostics (TSXV:VPT), an artificial intelligence healthcare stock focused on heart analysis technology, has received the European Union’s CE certification for its latest offering, VMS+ 4.0.

VMS+ 4.0 is designed to deliver a significant improvement in user experience through automated image processing, leading to streamlined workflow and a reduction in operator time without compromising accuracy.

The solution is based on Ventripoint’s proprietary Knowledge Based Reconstruction technology, which provides cost-effective volumetric cardiac measurements equivalent to magnetic resonance imaging (MRI).

The certification allows Ventripoint to continue commercialization efforts for VMS+ 4.0 in the E.U. and other countries that recognize the CE certification.

VMS+ 4.0 holds a medical device license in Canada and is under review by the U.S. Food and Drug Administration.

Ventripoint’s flagship VMS+ 3.2 is used by leading hospitals in the United States, European Union, Canada and the United Kingdom.

Leadership insights

“We are delighted to achieve CE mark certification and will introduce the enhanced capabilities of the new version to European cardiologists and healthcare providers,” Hugh MacNaught, Ventripoint’s president and chief executive officer, said in a statement. “This is a key step in our commercialization plan as we continue to advance our technology leadership and impact by advancing the state-of-the-art in echocardiography. The advances introduced in VMS+ 4.0 provide clinicians with the potential to image a broader range of patients, which expands our market opportunity. The engineering breakthroughs in this latest version of VMS+ provide healthcare providers with a powerful tool that delivers accurate and reliable cardiac output measurements in a more efficient manner, and without the restrictions associated with MRI.”

About Ventripoint Diagnostics

Ventripoint is an industry leader in applying AI technology to echocardiography.

Ventripoint Diagnostics stock (TSXV:VPT) is up by 6.67 per cent, trading at C$0.16 per share as of 9:45 am ET. The stock has given back 11.11 per cent year-over-year, but has gained 33.33 per cent since 2019.

Join the discussion: Find out what everybody’s saying about this AI healthcare stock on the Ventripoint Diagnostics Ltd. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

(Top image: Ventripoint Diagnostics)

Comment by jopatclo on Oct 28, 2024 12:38pm
 Good timing for Ventripoint for Health. The BEST automation and analysis of the PLANET GEN3EHO Interesting https://cardiacwire.com/newsletter/americas-cvd-problem-bac-cac-screening/ “Magic pills, magic shots, and magic procedures will have no impact on this problem. Only a wholesale change in culture of health in USA will move the needle.” Johns Hopkins cardiologist Joseph Marine, MD ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities